MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/alz.70823

Медицинская библиотека · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025

Discordant cerebrospinal fluid and positron emission tomography amyloid biomarkers in an APP mutation carrier presenting corticobasal syndrome.

Liu Feng-Tao, Li Xin-Yi, Lu Jia-Ying, Zuo Chuan-Tao

СтатьяКлинический случайПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

INTRODUCTION

While amyloid cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers are considered interchangeable indicators of Alzheimer's disease (AD) pathology, biomarker discrepancies can occur but remain poorly characterized.

METHODS

We evaluated 18F-florbetapir amyloid PET, 18F-Florzolotau PET (tau pathology), magnetic resonance imaging (MRI) findings, and CSF biomarkers in a 59-year-old man carrying the pathogenic APP p.K687Q mutation, who presented with possible corticobasal syndrome.

RESULTS

CSF analysis revealed reduced amyloid beta (Aβ)1-42 (503.44 pg/mL) and Aβ1-42/Aβ1-40 ratio (0.044), indicating amyloid pathology. Conversely, 18F-florbetapir PET was visually negative (standardized uptake value ratio [SUVR] 0.97; -11.8 Centiloids). 18F-Florzolotau PET demonstrated AD-typical tau deposition, whereas MRI revealed extensive white matter hyperintensities, enlarged perivascular spaces, and a temporal microbleed.

DISCUSSION: The observed discordance suggests that CSF and PET amyloid biomarkers can diverge in certain patients. Potential mechanisms include polymorphic Aβ fibrils lacking 18F-florbetapir binding sites, excess non-fibrillar aggregates, low fibril density, or contributions from cerebral amyloid angiopathy.

HIGHLIGHTS: CSF Aβ and 18F-florbetapir PET findings showed a mismatch in a patient with an APP mutation. Amyloid pathology should not be excluded despite negative 18F-florbetapir PET findings. Mismatch may reflect altered ligand binding or fibril structural variants. Comorbid cerebral amyloid angiopathy may contribute to biomarker discrepancies.

Для цитирования: Liu Feng-Tao, Li Xin-Yi, Lu Jia-Ying, Zuo Chuan-Tao. Discordant cerebrospinal fluid and positron emission tomography amyloid biomarkers in an APP mutation carrier presenting corticobasal syndrome.. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. DOI: 10.1002/alz.70823.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.